Ischemic heart disease is one of the most widespread cardiovascular diseases. In Republic of Moldova the total number of patients with ischemic heart disease is 30-40 thousand per 1 million population and is observed more of working age with important social value.
An attempt to substantially increase the effectiveness of complex treatment of ischemic heart disease (IHD) resulted in the introduction into clinical practice of metabolic pharmacotherapy in order to ensure cardiocytoprotection.